Skip to content
Open access

Advancing Therapeutics for Children with Medical Complexity: The Role of Model-Informed Precision Dosing and Genotype-Stratified Trials.

Oct 2026 · Clinical pharmacology and therapy · 0 citations · 8 references
Medicine

TL;DR

This work proposes a framework using genotype-stratified trials to characterize pharmacogenetic sources of variability, informing MIDD and MPID models while helping identify additional determinants of therapeutic response in CMC.

Abstract

Model-informed drug development (MIDD) and model-informed precision dosing (MIPD) increasingly guide drug development, regulatory decision-making, and individualized therapy but rely on robust data. Current models inadequately represent children with medical complexity (CMC), whose unique physiology, comorbidities, and polypharmacy contribute to substantial variability in drug exposure and response. We propose a framework using genotype-stratified trials to characterize pharmacogenetic sources of variability, informing MIDD and MPID models while helping identify additional determinants of therapeutic response in CMC.

Read PDF

Similar papers

Review Open access Oct 2026

Advancing functional treatment prediction for precision oncology.

Personalized cancer treatment requires stratification of patients based on biomarkers. Despite advances in biomarker-guided therapy, biomarkers are not always available or sufficient to predict treatment responses in individual patients. Functional ex vivo cancer models with the potential to assess therapeutic outcomes...

Eveline C. Smit, Zofia M. Komar, H. Blommestein et al. · 0 citations
Open access Sep 2026

Targeting Problems and Adhering to Standards: A Pathway to Uniform Clinical Laboratory Processes that Maximize the Benefits of Pharmacogenomics.

Specific laboratory practices that should be discontinued or established and followed as standard practice are proposed and ideal practices that would advance pharmacogenomics in clinical care are proposed.

E. Fieg, Benjamin Kerman, Lucas A. Berenbrok et al. · 0 citations
Open access Sep 2026

Integrating pharmacovigilance, pharmacokinetics and clinical outcomes in clozapine safety science.

Clozapine remains the most effective treatment for treatment-resistant schizophrenia, yet its use is constrained by concerns about safety and preventable adverse outcomes. Evidence on clozapine safety remains fragmented and methodologically heterogeneous, limiting translation into clinical practice. Pharmacovigilance,...

C. de las Cuevas · 0 citations
Open access 2026

Population pharmacokinetic modeling: A step toward precision dosing

Precision medicine is an approach to tailoring disease prevention and treatment based on individual patient characteristics, aiming to deliver the right treatment to the right patient at the right time. Precision dosing relies on clinical tools capable of integrating genotypic and phenotypic characteristics to inform i...

M. Jovanović · 0 citations
Open access Oct 2026

THE ROLE OF PHARMACOGENETICS IN PREDICTING DRUG RESPONSE AND ADVERSE DRUG REACTIONS

Give the same dose of the same drug to two patients, and one may be cured while the  other is harmed—a problem as old as prescribing itself. Much of that variability is  written in the genome. Pharmacogenetics, the study of how inherited variation modifies  drug response, has matured from a laboratory curiosity into a...

J. Sikarwar, Zunaira Amber, Nada Mohamme et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.